Related Articles
Efficacy of vonoprazan for 24-week maintenance therapy of patients with healed reflux esophagitis refractory to proton pump inhibitors
Evaluation of symptomatic reflux esophagitis in proton pump inhibitor users
Aurora kinase A (AURKA) and never in mitosis gene A-related kinase 6 (NEK6) genes are upregulated in erosive esophagitis and esophageal adenocarcinoma
Long‑term vonoprazan therapy is effective for controlling symptomatic proton pump inhibitor‑resistant gastroesophageal reflux disease
Vonoprazan 10 mg daily is effective for the treatment of patients with proton pump inhibitor‑resistant gastroesophageal reflux disease